Unknown

Dataset Information

0

Correcting Calcium Dysregulation in Chronic Heart Failure Using SERCA2a Gene Therapy.


ABSTRACT: Chronic heart failure (CHF) is a major contributor to cardiovascular disease and is the leading cause of hospitalization for those over the age of 65, which is estimated to account for close to seventy billion dollars in healthcare costs by 2030 in the US alone. The successful therapies for preventing and reversing CHF progression are urgently required. One strategy under active investigation is to restore dysregulated myocardial calcium (Ca2+), a hallmark of CHF. It is well established that intracellular Ca2+ concentrations are tightly regulated to control efficient myocardial systolic contraction and diastolic relaxation. Among the many cell surface proteins and intracellular organelles that act as the warp and woof of the regulatory network controlling intracellular Ca2+ signals in cardiomyocytes, sarco/endoplasmic reticulum Ca2+ ATPase type 2a (SERCA2a) undoubtedly plays a central role. SERCA2a is responsible for sequestrating cytosolic Ca2+ back into the sarcoplasmic reticulum during diastole, allowing for efficient uncoupling of actin-myosin and subsequent ventricular relaxation. Accumulating evidence has demonstrated that the expression of SERCA2a is downregulated in CHF, which subsequently contributes to severe systolic and diastolic dysfunction. Therefore, restoring SERCA2a expression and improving cardiomyocyte Ca2+ handling provides an excellent alternative to currently used transplantation and mechanical assist devices in the treatment of CHF. Indeed, advancements in safe and effective gene delivery techniques have led to the emergence of SERCA2a gene therapy as a potential therapeutic choice for CHF patients. This mini-review will succinctly detail the progression of SERCA2a gene therapy from its inception in plasmid and animal models, to its clinical trials in CHF patients, highlighting potential avenues for future work along the way.

SUBMITTER: Samuel TJ 

PROVIDER: S-EPMC5979534 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Correcting Calcium Dysregulation in Chronic Heart Failure Using SERCA2a Gene Therapy.

Samuel T Jake TJ   Rosenberry Ryan P RP   Lee Seungyong S   Pan Zui Z  

International journal of molecular sciences 20180405 4


Chronic heart failure (CHF) is a major contributor to cardiovascular disease and is the leading cause of hospitalization for those over the age of 65, which is estimated to account for close to seventy billion dollars in healthcare costs by 2030 in the US alone. The successful therapies for preventing and reversing CHF progression are urgently required. One strategy under active investigation is to restore dysregulated myocardial calcium (Ca<sup>2+</sup>), a hallmark of CHF. It is well establish  ...[more]

Similar Datasets

| S-EPMC10797746 | biostudies-literature
| S-EPMC4137356 | biostudies-literature
| S-EPMC3119354 | biostudies-other
| S-EPMC3341631 | biostudies-literature
| S-EPMC3443490 | biostudies-literature
| S-EPMC3732072 | biostudies-literature
| S-EPMC3753840 | biostudies-other
| S-EPMC1236548 | biostudies-literature
| S-EPMC5490943 | biostudies-literature
| S-EPMC3651893 | biostudies-literature